Monoamine Receptor Interaction Profiles of 4-aryl-substituted 2,5-dimethoxyphenethylamines (2C-BI Derivatives)
Overview
Affiliations
Many ring-substituted phenethylamines exert psychedelic effects that are thought to be primarily mediated by interactions with serotonergic 5-hydroxytryptamine 2 (5-HT) receptors. The 2,5-dimethoxyphenethylamine (2C derivative) core structure with small lipophilic substituents at the 4-position seems to be particularly favorable for psychedelic effects. In contrast, 2C derivatives with bulky lipophilic substituents at the 4-position of the phenyl ring tend to display antagonist behavior at serotonin 5-HT receptor sites. To gain a better understanding of agonist and antagonist behavior of substituted phenethylamines, binding affinities and functional activation and inhibition of a series of 4'-aryl substituted 2,5-dimethoxyphenethylamine (2C-BI derivatives) at various monoamine receptors were determined. In addition, the interactions of the compounds with monoamine transporters were assessed. Various 2C-BI derivatives potently bound to human serotonergic and adrenergic receptors and to rat and mouse trace amine-associated receptor 1. Additionally, 2C-BI-8 and 2C-BI-12 activated serotonin 5-HT and 5-HT receptors at submicromolar concentrations. 2C-BI-1 and 2C-BI-7 were the only 2C-BI derivatives to activate human trace amine-associated receptor 1. 2C-BI-3 and 2C-BI-4 interacted with monoamine transporters but with low overall potency. In conclusion, the tested 2C-BI derivatives displayed diverse pharmacological profiles. The relatively high affinities of various 2C-BI derivatives at the serotonin 5-HT receptor indicate a high steric tolerance of the binding pocket. Potent partial activation of the serotonin 5-HT receptor by 2C-BI-8 and 2C-BI-12 suggests that these substances may potentially exert psychedelic effects similar to other compounds of the 2C family.
Hemanth P, Nistala P, Nguyen V, Eltit J, Glennon R, Dukat M Front Pharmacol. 2023; 14:1101290.
PMID: 36762110 PMC: 9902381. DOI: 10.3389/fphar.2023.1101290.
Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity.
Warner-Schmidt J, Pittenger C, Stogniew M, Mandell B, Olmstead S, Kelmendi B Front Psychiatry. 2023; 13:1041277.
PMID: 36704743 PMC: 9873307. DOI: 10.3389/fpsyt.2022.1041277.
Halberstadt A, Luethi D, Hoener M, Trachsel D, Brandt S, Liechti M Psychopharmacology (Berl). 2022; 240(1):115-126.
PMID: 36477925 PMC: 9816194. DOI: 10.1007/s00213-022-06279-2.
Kolaczynska K, Luethi D, Trachsel D, Hoener M, Liechti M Front Pharmacol. 2022; 12:794254.
PMID: 35222010 PMC: 8865417. DOI: 10.3389/fphar.2021.794254.
New psychoactive substances: a review and updates.
Shafi A, Berry A, Sumnall H, Wood D, Tracy D Ther Adv Psychopharmacol. 2021; 10:2045125320967197.
PMID: 33414905 PMC: 7750892. DOI: 10.1177/2045125320967197.